Merck KGaA’s Mavenclad (cladribine) tablets have been recommended by the National Institute for Health and Care Excellence (NICE) to treat a broader group of multiple sclerosis (MS) patients. The ...

The medication, which will be rolled out to patients with relapsing-remitting MS, is thought to be the first in Europe to be ...

The list price of Mavenclad is around £2,050 per 10mg tablet, although, Merck is providing it to the NHS in England at a ...

US pharma group Merck said the UAE Ministry of Health and Prevention has approved the registration of its Mavenclad (cladribine tablets) for the treatment of adult patients with highly active ...

If approved, Mavenclad could offer a more patient-friendly ... Results of CLARITY showed the tablets reduced annualised relapse rate by 67% and the risk of disease progress by 82% versus placebo.